nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—CYP1A2—type 2 diabetes mellitus	0.148	0.447	CbGaD
Vemurafenib—CYP3A4—type 2 diabetes mellitus	0.0977	0.296	CbGaD
Vemurafenib—ALB—type 2 diabetes mellitus	0.0852	0.258	CbGaD
Vemurafenib—ORM1—Nateglinide—type 2 diabetes mellitus	0.0493	0.113	CbGbCtD
Vemurafenib—ALB—Gliclazide—type 2 diabetes mellitus	0.0322	0.0737	CbGbCtD
Vemurafenib—ABCC1—Glyburide—type 2 diabetes mellitus	0.0304	0.0695	CbGbCtD
Vemurafenib—ALB—Repaglinide—type 2 diabetes mellitus	0.0303	0.0693	CbGbCtD
Vemurafenib—ALB—Rosiglitazone—type 2 diabetes mellitus	0.0253	0.0578	CbGbCtD
Vemurafenib—ALB—Valsartan—type 2 diabetes mellitus	0.0223	0.0511	CbGbCtD
Vemurafenib—ALB—Nateglinide—type 2 diabetes mellitus	0.0207	0.0475	CbGbCtD
Vemurafenib—ABCG2—Glyburide—type 2 diabetes mellitus	0.0203	0.0465	CbGbCtD
Vemurafenib—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.0151	0.0346	CbGbCtD
Vemurafenib—ALB—Glyburide—type 2 diabetes mellitus	0.014	0.0321	CbGbCtD
Vemurafenib—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0135	0.0309	CbGbCtD
Vemurafenib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0133	0.0305	CbGbCtD
Vemurafenib—ALB—Losartan—type 2 diabetes mellitus	0.0128	0.0293	CbGbCtD
Vemurafenib—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0124	0.0285	CbGbCtD
Vemurafenib—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.0119	0.0272	CbGbCtD
Vemurafenib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0119	0.0272	CbGbCtD
Vemurafenib—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.0112	0.0257	CbGbCtD
Vemurafenib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0108	0.0248	CbGbCtD
Vemurafenib—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0102	0.0234	CbGbCtD
Vemurafenib—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0098	0.0224	CbGbCtD
Vemurafenib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00948	0.0217	CbGbCtD
Vemurafenib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00858	0.0196	CbGbCtD
Vemurafenib—CYP1A2—Losartan—type 2 diabetes mellitus	0.00766	0.0175	CbGbCtD
Vemurafenib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0065	0.0149	CbGbCtD
Vemurafenib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00623	0.0143	CbGbCtD
Vemurafenib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00623	0.0143	CbGbCtD
Vemurafenib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00589	0.0135	CbGbCtD
Vemurafenib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00439	0.0101	CbGbCtD
Vemurafenib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00402	0.00919	CbGbCtD
Vemurafenib—Etoricoxib—CYP2E1—type 2 diabetes mellitus	0.0009	0.313	CrCbGaD
Vemurafenib—Etoricoxib—CYP1A2—type 2 diabetes mellitus	0.000856	0.297	CrCbGaD
Vemurafenib—Etoricoxib—CYP3A4—type 2 diabetes mellitus	0.000567	0.197	CrCbGaD
Vemurafenib—Etoricoxib—PTGS2—type 2 diabetes mellitus	0.000555	0.193	CrCbGaD
Vemurafenib—RAF1—islet of Langerhans—type 2 diabetes mellitus	0.000305	0.0959	CbGeAlD
Vemurafenib—BRAF—adipose tissue—type 2 diabetes mellitus	0.000292	0.0918	CbGeAlD
Vemurafenib—RAF1—nephron tubule—type 2 diabetes mellitus	0.000246	0.0772	CbGeAlD
Vemurafenib—RAF1—cardiovascular system—type 2 diabetes mellitus	0.000221	0.0694	CbGeAlD
Vemurafenib—RAF1—kidney—type 2 diabetes mellitus	0.000216	0.0679	CbGeAlD
Vemurafenib—RAF1—pancreas—type 2 diabetes mellitus	0.000214	0.0674	CbGeAlD
Vemurafenib—RAF1—cortex of kidney—type 2 diabetes mellitus	0.00021	0.0661	CbGeAlD
Vemurafenib—BRAF—liver—type 2 diabetes mellitus	0.000205	0.0644	CbGeAlD
Vemurafenib—RAF1—adipose tissue—type 2 diabetes mellitus	0.000194	0.0612	CbGeAlD
Vemurafenib—Chills—Metformin—type 2 diabetes mellitus	0.000172	0.00139	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000171	0.00138	CcSEcCtD
Vemurafenib—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000171	0.00138	CcSEcCtD
Vemurafenib—Myalgia—Gliclazide—type 2 diabetes mellitus	0.00017	0.00137	CcSEcCtD
Vemurafenib—Arthralgia—Gliclazide—type 2 diabetes mellitus	0.00017	0.00137	CcSEcCtD
Vemurafenib—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000169	0.00137	CcSEcCtD
Vemurafenib—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000169	0.00137	CcSEcCtD
Vemurafenib—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000169	0.00137	CcSEcCtD
Vemurafenib—Hypotension—Glyburide—type 2 diabetes mellitus	0.000169	0.00137	CcSEcCtD
Vemurafenib—Nausea—Repaglinide—type 2 diabetes mellitus	0.000169	0.00136	CcSEcCtD
Vemurafenib—Asthenia—Glipizide—type 2 diabetes mellitus	0.000169	0.00136	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000168	0.00136	CcSEcCtD
Vemurafenib—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000168	0.00136	CcSEcCtD
Vemurafenib—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.000168	0.00135	CcSEcCtD
Vemurafenib—Erythema—Metformin—type 2 diabetes mellitus	0.000167	0.00135	CcSEcCtD
Vemurafenib—Malnutrition—Metformin—type 2 diabetes mellitus	0.000167	0.00135	CcSEcCtD
Vemurafenib—Pruritus—Glipizide—type 2 diabetes mellitus	0.000166	0.00134	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Ramipril—type 2 diabetes mellitus	0.000166	0.00134	CcSEcCtD
Vemurafenib—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000166	0.00134	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	0.000165	0.00133	CcSEcCtD
Vemurafenib—Angiopathy—Irbesartan—type 2 diabetes mellitus	0.000164	0.00132	CcSEcCtD
Vemurafenib—Dysgeusia—Metformin—type 2 diabetes mellitus	0.000163	0.00132	CcSEcCtD
Vemurafenib—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.000163	0.00131	CcSEcCtD
Vemurafenib—Chills—Irbesartan—type 2 diabetes mellitus	0.000162	0.00131	CcSEcCtD
Vemurafenib—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000162	0.00131	CcSEcCtD
Vemurafenib—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000162	0.00131	CcSEcCtD
Vemurafenib—Infection—Gliclazide—type 2 diabetes mellitus	0.000162	0.0013	CcSEcCtD
Vemurafenib—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000161	0.0013	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Ramipril—type 2 diabetes mellitus	0.000161	0.0013	CcSEcCtD
Vemurafenib—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000161	0.0013	CcSEcCtD
Vemurafenib—Erythema multiforme—Losartan—type 2 diabetes mellitus	0.000161	0.0013	CcSEcCtD
Vemurafenib—Cough—Valsartan—type 2 diabetes mellitus	0.00016	0.00129	CcSEcCtD
Vemurafenib—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00016	0.00129	CcSEcCtD
Vemurafenib—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000159	0.00129	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Ramipril—type 2 diabetes mellitus	0.000159	0.00128	CcSEcCtD
Vemurafenib—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000158	0.00127	CcSEcCtD
Vemurafenib—Cough—Orlistat—type 2 diabetes mellitus	0.000158	0.00127	CcSEcCtD
Vemurafenib—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000158	0.00127	CcSEcCtD
Vemurafenib—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.000157	0.00127	CcSEcCtD
Vemurafenib—Erythema—Irbesartan—type 2 diabetes mellitus	0.000157	0.00127	CcSEcCtD
Vemurafenib—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.000157	0.00127	CcSEcCtD
Vemurafenib—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000157	0.00127	CcSEcCtD
Vemurafenib—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000157	0.00126	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000156	0.00126	CcSEcCtD
Vemurafenib—Myalgia—Valsartan—type 2 diabetes mellitus	0.000156	0.00126	CcSEcCtD
Vemurafenib—Arthralgia—Valsartan—type 2 diabetes mellitus	0.000156	0.00126	CcSEcCtD
Vemurafenib—Dizziness—Glipizide—type 2 diabetes mellitus	0.000156	0.00126	CcSEcCtD
Vemurafenib—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000155	0.00125	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000155	0.00125	CcSEcCtD
Vemurafenib—Angiopathy—Losartan—type 2 diabetes mellitus	0.000154	0.00125	CcSEcCtD
Vemurafenib—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000154	0.00124	CcSEcCtD
Vemurafenib—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000154	0.00124	CcSEcCtD
Vemurafenib—Myalgia—Orlistat—type 2 diabetes mellitus	0.000154	0.00124	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000153	0.00123	CcSEcCtD
Vemurafenib—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000152	0.00123	CcSEcCtD
Vemurafenib—Alopecia—Losartan—type 2 diabetes mellitus	0.00015	0.00121	CcSEcCtD
Vemurafenib—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.00015	0.00121	CcSEcCtD
Vemurafenib—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.00015	0.00121	CcSEcCtD
Vemurafenib—Vomiting—Glipizide—type 2 diabetes mellitus	0.00015	0.00121	CcSEcCtD
Vemurafenib—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.000149	0.00121	CcSEcCtD
Vemurafenib—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000149	0.0012	CcSEcCtD
Vemurafenib—Infection—Valsartan—type 2 diabetes mellitus	0.000148	0.0012	CcSEcCtD
Vemurafenib—Rash—Glipizide—type 2 diabetes mellitus	0.000148	0.0012	CcSEcCtD
Vemurafenib—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000148	0.0012	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000148	0.0012	CcSEcCtD
Vemurafenib—Erythema—Losartan—type 2 diabetes mellitus	0.000148	0.00119	CcSEcCtD
Vemurafenib—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000148	0.00119	CcSEcCtD
Vemurafenib—Headache—Glipizide—type 2 diabetes mellitus	0.000147	0.00119	CcSEcCtD
Vemurafenib—Infection—Orlistat—type 2 diabetes mellitus	0.000147	0.00118	CcSEcCtD
Vemurafenib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000146	0.00118	CcSEcCtD
Vemurafenib—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000145	0.00117	CcSEcCtD
Vemurafenib—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000145	0.00117	CcSEcCtD
Vemurafenib—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000145	0.00117	CcSEcCtD
Vemurafenib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000145	0.00117	CcSEcCtD
Vemurafenib—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000145	0.00117	CcSEcCtD
Vemurafenib—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000144	0.00116	CcSEcCtD
Vemurafenib—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000143	0.00116	CcSEcCtD
Vemurafenib—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000143	0.00116	CcSEcCtD
Vemurafenib—Back pain—Losartan—type 2 diabetes mellitus	0.000143	0.00116	CcSEcCtD
Vemurafenib—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000142	0.00115	CcSEcCtD
Vemurafenib—Myalgia—Metformin—type 2 diabetes mellitus	0.000142	0.00115	CcSEcCtD
Vemurafenib—Headache—Pioglitazone—type 2 diabetes mellitus	0.000141	0.00114	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000141	0.00114	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00014	0.00113	CcSEcCtD
Vemurafenib—Fatigue—Gliclazide—type 2 diabetes mellitus	0.00014	0.00113	CcSEcCtD
Vemurafenib—Nausea—Glipizide—type 2 diabetes mellitus	0.00014	0.00113	CcSEcCtD
Vemurafenib—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00014	0.00113	CcSEcCtD
Vemurafenib—Hypotension—Valsartan—type 2 diabetes mellitus	0.00014	0.00113	CcSEcCtD
Vemurafenib—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000139	0.00112	CcSEcCtD
Vemurafenib—Constipation—Gliclazide—type 2 diabetes mellitus	0.000139	0.00112	CcSEcCtD
Vemurafenib—Rash—Glimepiride—type 2 diabetes mellitus	0.000138	0.00112	CcSEcCtD
Vemurafenib—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000138	0.00112	CcSEcCtD
Vemurafenib—Rash—Sitagliptin—type 2 diabetes mellitus	0.000138	0.00111	CcSEcCtD
Vemurafenib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000138	0.00111	CcSEcCtD
Vemurafenib—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000138	0.00111	CcSEcCtD
Vemurafenib—Headache—Glimepiride—type 2 diabetes mellitus	0.000138	0.00111	CcSEcCtD
Vemurafenib—Cough—Irbesartan—type 2 diabetes mellitus	0.000137	0.00111	CcSEcCtD
Vemurafenib—Headache—Sitagliptin—type 2 diabetes mellitus	0.000137	0.00111	CcSEcCtD
Vemurafenib—RAF1—liver—type 2 diabetes mellitus	0.000136	0.0429	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000136	0.0011	CcSEcCtD
Vemurafenib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000136	0.00109	CcSEcCtD
Vemurafenib—Infection—Metformin—type 2 diabetes mellitus	0.000135	0.00109	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000134	0.00109	CcSEcCtD
Vemurafenib—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000134	0.00108	CcSEcCtD
Vemurafenib—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000134	0.00108	CcSEcCtD
Vemurafenib—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000133	0.00108	CcSEcCtD
Vemurafenib—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000133	0.00108	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000133	0.00107	CcSEcCtD
Vemurafenib—Skin disorder—Metformin—type 2 diabetes mellitus	0.000132	0.00107	CcSEcCtD
Vemurafenib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000131	0.00106	CcSEcCtD
Vemurafenib—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000131	0.00106	CcSEcCtD
Vemurafenib—Nausea—Glimepiride—type 2 diabetes mellitus	0.00013	0.00105	CcSEcCtD
Vemurafenib—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00013	0.00105	CcSEcCtD
Vemurafenib—Asthenia—Glyburide—type 2 diabetes mellitus	0.00013	0.00105	CcSEcCtD
Vemurafenib—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.00013	0.00105	CcSEcCtD
Vemurafenib—Cough—Losartan—type 2 diabetes mellitus	0.000129	0.00104	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000129	0.00104	CcSEcCtD
Vemurafenib—Alopecia—Ramipril—type 2 diabetes mellitus	0.000129	0.00104	CcSEcCtD
Vemurafenib—Fatigue—Valsartan—type 2 diabetes mellitus	0.000129	0.00104	CcSEcCtD
Vemurafenib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000129	0.00104	CcSEcCtD
Vemurafenib—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000128	0.00104	CcSEcCtD
Vemurafenib—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000128	0.00104	CcSEcCtD
Vemurafenib—Pruritus—Glyburide—type 2 diabetes mellitus	0.000128	0.00103	CcSEcCtD
Vemurafenib—Constipation—Valsartan—type 2 diabetes mellitus	0.000128	0.00103	CcSEcCtD
Vemurafenib—Infection—Irbesartan—type 2 diabetes mellitus	0.000128	0.00103	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000127	0.00103	CcSEcCtD
Vemurafenib—Fatigue—Orlistat—type 2 diabetes mellitus	0.000127	0.00103	CcSEcCtD
Vemurafenib—Hypotension—Metformin—type 2 diabetes mellitus	0.000127	0.00103	CcSEcCtD
Vemurafenib—Erythema—Ramipril—type 2 diabetes mellitus	0.000127	0.00102	CcSEcCtD
Vemurafenib—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000127	0.00102	CcSEcCtD
Vemurafenib—Myalgia—Losartan—type 2 diabetes mellitus	0.000126	0.00102	CcSEcCtD
Vemurafenib—Arthralgia—Losartan—type 2 diabetes mellitus	0.000126	0.00102	CcSEcCtD
Vemurafenib—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000126	0.00102	CcSEcCtD
Vemurafenib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000126	0.00102	CcSEcCtD
Vemurafenib—Rash—Bromocriptine—type 2 diabetes mellitus	0.000125	0.00101	CcSEcCtD
Vemurafenib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000125	0.00101	CcSEcCtD
Vemurafenib—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000125	0.00101	CcSEcCtD
Vemurafenib—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000124	0.001	CcSEcCtD
Vemurafenib—Headache—Bromocriptine—type 2 diabetes mellitus	0.000124	0.001	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000124	0.001	CcSEcCtD
Vemurafenib—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000124	0.001	CcSEcCtD
Vemurafenib—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000121	0.000975	CcSEcCtD
Vemurafenib—Infection—Losartan—type 2 diabetes mellitus	0.00012	0.000969	CcSEcCtD
Vemurafenib—Hypotension—Irbesartan—type 2 diabetes mellitus	0.00012	0.000968	CcSEcCtD
Vemurafenib—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00012	0.000967	CcSEcCtD
Vemurafenib—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000118	0.000956	CcSEcCtD
Vemurafenib—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000118	0.000954	CcSEcCtD
Vemurafenib—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000118	0.00095	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000117	0.000948	CcSEcCtD
Vemurafenib—Fatigue—Metformin—type 2 diabetes mellitus	0.000117	0.000947	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000117	0.000944	CcSEcCtD
Vemurafenib—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000117	0.000942	CcSEcCtD
Vemurafenib—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000117	0.000941	CcSEcCtD
Vemurafenib—Constipation—Metformin—type 2 diabetes mellitus	0.000116	0.000939	CcSEcCtD
Vemurafenib—Vomiting—Glyburide—type 2 diabetes mellitus	0.000115	0.000929	CcSEcCtD
Vemurafenib—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000115	0.000928	CcSEcCtD
Vemurafenib—Rash—Glyburide—type 2 diabetes mellitus	0.000114	0.000921	CcSEcCtD
Vemurafenib—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000114	0.000921	CcSEcCtD
Vemurafenib—Headache—Glyburide—type 2 diabetes mellitus	0.000113	0.000915	CcSEcCtD
Vemurafenib—Hypotension—Losartan—type 2 diabetes mellitus	0.000113	0.000911	CcSEcCtD
Vemurafenib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000112	0.000901	CcSEcCtD
Vemurafenib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000111	0.000898	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000111	0.000894	CcSEcCtD
Vemurafenib—Cough—Ramipril—type 2 diabetes mellitus	0.000111	0.000894	CcSEcCtD
Vemurafenib—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000111	0.000893	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.00011	0.000888	CcSEcCtD
Vemurafenib—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.00011	0.000888	CcSEcCtD
Vemurafenib—Constipation—Irbesartan—type 2 diabetes mellitus	0.00011	0.000886	CcSEcCtD
Vemurafenib—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000109	0.000878	CcSEcCtD
Vemurafenib—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000108	0.000872	CcSEcCtD
Vemurafenib—Myalgia—Ramipril—type 2 diabetes mellitus	0.000108	0.000872	CcSEcCtD
Vemurafenib—Nausea—Glyburide—type 2 diabetes mellitus	0.000108	0.000868	CcSEcCtD
Vemurafenib—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000108	0.000868	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000107	0.000866	CcSEcCtD
Vemurafenib—Asthenia—Valsartan—type 2 diabetes mellitus	0.000107	0.000865	CcSEcCtD
Vemurafenib—Asthenia—Orlistat—type 2 diabetes mellitus	0.000106	0.000855	CcSEcCtD
Vemurafenib—Pruritus—Valsartan—type 2 diabetes mellitus	0.000106	0.000853	CcSEcCtD
Vemurafenib—ABCC1—cortex of kidney—type 2 diabetes mellitus	0.000105	0.033	CbGeAlD
Vemurafenib—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000105	0.000848	CcSEcCtD
Vemurafenib—Pruritus—Orlistat—type 2 diabetes mellitus	0.000104	0.000843	CcSEcCtD
Vemurafenib—Fatigue—Losartan—type 2 diabetes mellitus	0.000104	0.000841	CcSEcCtD
Vemurafenib—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000104	0.000836	CcSEcCtD
Vemurafenib—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000103	0.000834	CcSEcCtD
Vemurafenib—Constipation—Losartan—type 2 diabetes mellitus	0.000103	0.000834	CcSEcCtD
Vemurafenib—Rash—Gliclazide—type 2 diabetes mellitus	0.000103	0.000827	CcSEcCtD
Vemurafenib—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000102	0.000827	CcSEcCtD
Vemurafenib—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000102	0.000825	CcSEcCtD
Vemurafenib—Headache—Gliclazide—type 2 diabetes mellitus	0.000102	0.000822	CcSEcCtD
Vemurafenib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000102	0.0319	CbGeAlD
Vemurafenib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000102	0.00082	CcSEcCtD
Vemurafenib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000101	0.000819	CcSEcCtD
Vemurafenib—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000101	0.000815	CcSEcCtD
Vemurafenib—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000101	0.000812	CcSEcCtD
Vemurafenib—Dizziness—Valsartan—type 2 diabetes mellitus	9.88e-05	0.000797	CcSEcCtD
Vemurafenib—Dizziness—Orlistat—type 2 diabetes mellitus	9.76e-05	0.000788	CcSEcCtD
Vemurafenib—Asthenia—Metformin—type 2 diabetes mellitus	9.76e-05	0.000788	CcSEcCtD
Vemurafenib—ABCC1—adipose tissue—type 2 diabetes mellitus	9.72e-05	0.0306	CbGeAlD
Vemurafenib—Hypotension—Ramipril—type 2 diabetes mellitus	9.68e-05	0.000781	CcSEcCtD
Vemurafenib—Nausea—Gliclazide—type 2 diabetes mellitus	9.66e-05	0.000779	CcSEcCtD
Vemurafenib—Pruritus—Metformin—type 2 diabetes mellitus	9.62e-05	0.000777	CcSEcCtD
Vemurafenib—Body temperature increased—Losartan—type 2 diabetes mellitus	9.55e-05	0.000771	CcSEcCtD
Vemurafenib—Vomiting—Valsartan—type 2 diabetes mellitus	9.5e-05	0.000767	CcSEcCtD
Vemurafenib—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	9.46e-05	0.000763	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	9.44e-05	0.000762	CcSEcCtD
Vemurafenib—Rash—Valsartan—type 2 diabetes mellitus	9.42e-05	0.00076	CcSEcCtD
Vemurafenib—ORM1—liver—type 2 diabetes mellitus	9.42e-05	0.0296	CbGeAlD
Vemurafenib—Dermatitis—Valsartan—type 2 diabetes mellitus	9.41e-05	0.000759	CcSEcCtD
Vemurafenib—Vomiting—Orlistat—type 2 diabetes mellitus	9.38e-05	0.000757	CcSEcCtD
Vemurafenib—Headache—Valsartan—type 2 diabetes mellitus	9.36e-05	0.000755	CcSEcCtD
Vemurafenib—Diarrhoea—Metformin—type 2 diabetes mellitus	9.31e-05	0.000751	CcSEcCtD
Vemurafenib—Rash—Orlistat—type 2 diabetes mellitus	9.31e-05	0.000751	CcSEcCtD
Vemurafenib—Dermatitis—Orlistat—type 2 diabetes mellitus	9.3e-05	0.00075	CcSEcCtD
Vemurafenib—Headache—Orlistat—type 2 diabetes mellitus	9.25e-05	0.000746	CcSEcCtD
Vemurafenib—Asthenia—Irbesartan—type 2 diabetes mellitus	9.21e-05	0.000743	CcSEcCtD
Vemurafenib—Pruritus—Irbesartan—type 2 diabetes mellitus	9.08e-05	0.000733	CcSEcCtD
Vemurafenib—Decreased appetite—Ramipril—type 2 diabetes mellitus	9e-05	0.000727	CcSEcCtD
Vemurafenib—Dizziness—Metformin—type 2 diabetes mellitus	8.99e-05	0.000726	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	8.94e-05	0.000722	CcSEcCtD
Vemurafenib—Fatigue—Ramipril—type 2 diabetes mellitus	8.93e-05	0.000721	CcSEcCtD
Vemurafenib—Hypersensitivity—Losartan—type 2 diabetes mellitus	8.9e-05	0.000718	CcSEcCtD
Vemurafenib—Nausea—Valsartan—type 2 diabetes mellitus	8.87e-05	0.000716	CcSEcCtD
Vemurafenib—Constipation—Ramipril—type 2 diabetes mellitus	8.86e-05	0.000715	CcSEcCtD
Vemurafenib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	8.78e-05	0.000709	CcSEcCtD
Vemurafenib—Nausea—Orlistat—type 2 diabetes mellitus	8.77e-05	0.000708	CcSEcCtD
Vemurafenib—Asthenia—Losartan—type 2 diabetes mellitus	8.67e-05	0.0007	CcSEcCtD
Vemurafenib—Vomiting—Metformin—type 2 diabetes mellitus	8.65e-05	0.000698	CcSEcCtD
Vemurafenib—Rash—Metformin—type 2 diabetes mellitus	8.58e-05	0.000692	CcSEcCtD
Vemurafenib—Dermatitis—Metformin—type 2 diabetes mellitus	8.57e-05	0.000692	CcSEcCtD
Vemurafenib—Pruritus—Losartan—type 2 diabetes mellitus	8.55e-05	0.00069	CcSEcCtD
Vemurafenib—Headache—Metformin—type 2 diabetes mellitus	8.52e-05	0.000688	CcSEcCtD
Vemurafenib—Dizziness—Irbesartan—type 2 diabetes mellitus	8.49e-05	0.000685	CcSEcCtD
Vemurafenib—Diarrhoea—Losartan—type 2 diabetes mellitus	8.26e-05	0.000667	CcSEcCtD
Vemurafenib—ALB—liver—type 2 diabetes mellitus	8.26e-05	0.026	CbGeAlD
Vemurafenib—Body temperature increased—Ramipril—type 2 diabetes mellitus	8.19e-05	0.000661	CcSEcCtD
Vemurafenib—Vomiting—Irbesartan—type 2 diabetes mellitus	8.16e-05	0.000659	CcSEcCtD
Vemurafenib—Rash—Irbesartan—type 2 diabetes mellitus	8.09e-05	0.000653	CcSEcCtD
Vemurafenib—Dermatitis—Irbesartan—type 2 diabetes mellitus	8.09e-05	0.000653	CcSEcCtD
Vemurafenib—Nausea—Metformin—type 2 diabetes mellitus	8.08e-05	0.000652	CcSEcCtD
Vemurafenib—ABCG2—adipose tissue—type 2 diabetes mellitus	8.05e-05	0.0253	CbGeAlD
Vemurafenib—Headache—Irbesartan—type 2 diabetes mellitus	8.04e-05	0.000649	CcSEcCtD
Vemurafenib—Dizziness—Losartan—type 2 diabetes mellitus	7.99e-05	0.000645	CcSEcCtD
Vemurafenib—Vomiting—Losartan—type 2 diabetes mellitus	7.68e-05	0.00062	CcSEcCtD
Vemurafenib—Hypersensitivity—Ramipril—type 2 diabetes mellitus	7.63e-05	0.000616	CcSEcCtD
Vemurafenib—Nausea—Irbesartan—type 2 diabetes mellitus	7.62e-05	0.000615	CcSEcCtD
Vemurafenib—Rash—Losartan—type 2 diabetes mellitus	7.62e-05	0.000615	CcSEcCtD
Vemurafenib—Dermatitis—Losartan—type 2 diabetes mellitus	7.61e-05	0.000614	CcSEcCtD
Vemurafenib—Headache—Losartan—type 2 diabetes mellitus	7.57e-05	0.000611	CcSEcCtD
Vemurafenib—Asthenia—Ramipril—type 2 diabetes mellitus	7.43e-05	0.0006	CcSEcCtD
Vemurafenib—Pruritus—Ramipril—type 2 diabetes mellitus	7.33e-05	0.000592	CcSEcCtD
Vemurafenib—Nausea—Losartan—type 2 diabetes mellitus	7.18e-05	0.000579	CcSEcCtD
Vemurafenib—Diarrhoea—Ramipril—type 2 diabetes mellitus	7.09e-05	0.000572	CcSEcCtD
Vemurafenib—Dizziness—Ramipril—type 2 diabetes mellitus	6.85e-05	0.000553	CcSEcCtD
Vemurafenib—ABCC1—liver—type 2 diabetes mellitus	6.82e-05	0.0214	CbGeAlD
Vemurafenib—Vomiting—Ramipril—type 2 diabetes mellitus	6.59e-05	0.000532	CcSEcCtD
Vemurafenib—Rash—Ramipril—type 2 diabetes mellitus	6.53e-05	0.000527	CcSEcCtD
Vemurafenib—Dermatitis—Ramipril—type 2 diabetes mellitus	6.52e-05	0.000527	CcSEcCtD
Vemurafenib—Headache—Ramipril—type 2 diabetes mellitus	6.49e-05	0.000524	CcSEcCtD
Vemurafenib—CYP3A4—kidney—type 2 diabetes mellitus	6.22e-05	0.0196	CbGeAlD
Vemurafenib—Nausea—Ramipril—type 2 diabetes mellitus	6.15e-05	0.000497	CcSEcCtD
Vemurafenib—CYP2D6—kidney—type 2 diabetes mellitus	6.12e-05	0.0192	CbGeAlD
Vemurafenib—ABCG2—liver—type 2 diabetes mellitus	5.64e-05	0.0177	CbGeAlD
Vemurafenib—CYP1A2—liver—type 2 diabetes mellitus	5.43e-05	0.0171	CbGeAlD
Vemurafenib—CYP3A4—liver—type 2 diabetes mellitus	3.93e-05	0.0124	CbGeAlD
Vemurafenib—CYP2D6—liver—type 2 diabetes mellitus	3.87e-05	0.0122	CbGeAlD
Vemurafenib—BRAF—Signaling Pathways—RELA—type 2 diabetes mellitus	4.31e-06	4.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—AKT1—type 2 diabetes mellitus	4.3e-06	4.18e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	4.29e-06	4.17e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—INS—type 2 diabetes mellitus	4.28e-06	4.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	4.27e-06	4.16e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	4.25e-06	4.14e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	4.25e-06	4.14e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	4.25e-06	4.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.24e-06	4.13e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—type 2 diabetes mellitus	4.24e-06	4.12e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	4.24e-06	4.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LEP—type 2 diabetes mellitus	4.23e-06	4.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOE—type 2 diabetes mellitus	4.23e-06	4.11e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	4.23e-06	4.11e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP3A4—type 2 diabetes mellitus	4.21e-06	4.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—type 2 diabetes mellitus	4.19e-06	4.08e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	4.19e-06	4.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.18e-06	4.07e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GLP1R—type 2 diabetes mellitus	4.18e-06	4.06e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—SLC2A4—type 2 diabetes mellitus	4.14e-06	4.03e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GCG—type 2 diabetes mellitus	4.14e-06	4.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—type 2 diabetes mellitus	4.14e-06	4.02e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—type 2 diabetes mellitus	4.1e-06	3.99e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	4e-06	3.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.99e-06	3.88e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	3.94e-06	3.83e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	3.94e-06	3.83e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	3.94e-06	3.83e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—type 2 diabetes mellitus	3.93e-06	3.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC2A2—type 2 diabetes mellitus	3.9e-06	3.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NFKB1—type 2 diabetes mellitus	3.89e-06	3.78e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.89e-06	3.78e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	3.87e-06	3.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—type 2 diabetes mellitus	3.87e-06	3.76e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—type 2 diabetes mellitus	3.84e-06	3.74e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	3.83e-06	3.73e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTR—type 2 diabetes mellitus	3.82e-06	3.72e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CPT1A—type 2 diabetes mellitus	3.82e-06	3.72e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.77e-06	3.67e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—INS—type 2 diabetes mellitus	3.77e-06	3.67e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3R1—type 2 diabetes mellitus	3.76e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NOS3—type 2 diabetes mellitus	3.76e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	3.75e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NAMPT—type 2 diabetes mellitus	3.75e-06	3.64e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	3.74e-06	3.64e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	3.72e-06	3.62e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LIPC—type 2 diabetes mellitus	3.72e-06	3.62e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GCK—type 2 diabetes mellitus	3.72e-06	3.62e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HBA1—type 2 diabetes mellitus	3.72e-06	3.62e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SRC—type 2 diabetes mellitus	3.72e-06	3.62e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—type 2 diabetes mellitus	3.71e-06	3.61e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP11A1—type 2 diabetes mellitus	3.7e-06	3.6e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.67e-06	3.57e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.63e-06	3.54e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	3.63e-06	3.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SRC—type 2 diabetes mellitus	3.62e-06	3.53e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—type 2 diabetes mellitus	3.62e-06	3.52e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	3.62e-06	3.52e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	3.62e-06	3.52e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	3.62e-06	3.52e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	3.62e-06	3.52e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—INS—type 2 diabetes mellitus	3.61e-06	3.51e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	3.6e-06	3.51e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	3.59e-06	3.49e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.57e-06	3.47e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GNB3—type 2 diabetes mellitus	3.57e-06	3.47e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	3.56e-06	3.47e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	3.56e-06	3.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.55e-06	3.46e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HMOX1—type 2 diabetes mellitus	3.55e-06	3.45e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAT—type 2 diabetes mellitus	3.5e-06	3.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.49e-06	3.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.49e-06	3.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.48e-06	3.38e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	3.48e-06	3.38e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	3.47e-06	3.37e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—type 2 diabetes mellitus	3.45e-06	3.36e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—type 2 diabetes mellitus	3.43e-06	3.34e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	3.42e-06	3.32e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	3.42e-06	3.32e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOB—type 2 diabetes mellitus	3.4e-06	3.31e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SRC—type 2 diabetes mellitus	3.39e-06	3.29e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	3.35e-06	3.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SRC—type 2 diabetes mellitus	3.35e-06	3.26e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	3.34e-06	3.25e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	3.34e-06	3.25e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	3.34e-06	3.25e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	3.33e-06	3.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.32e-06	3.23e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SRC—type 2 diabetes mellitus	3.32e-06	3.23e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	3.31e-06	3.22e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3R1—type 2 diabetes mellitus	3.3e-06	3.21e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—type 2 diabetes mellitus	3.3e-06	3.21e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.3e-06	3.21e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	3.28e-06	3.19e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—type 2 diabetes mellitus	3.26e-06	3.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	3.25e-06	3.16e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—LPL—type 2 diabetes mellitus	3.25e-06	3.16e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	3.22e-06	3.13e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	3.2e-06	3.12e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	3.18e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	3.18e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—type 2 diabetes mellitus	3.18e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX1—type 2 diabetes mellitus	3.17e-06	3.08e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.17e-06	3.08e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.17e-06	3.08e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CD36—type 2 diabetes mellitus	3.09e-06	3e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	3.05e-06	2.97e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	3.05e-06	2.96e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.03e-06	2.95e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	3.02e-06	2.94e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	3.02e-06	2.94e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	3.01e-06	2.93e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—type 2 diabetes mellitus	3.01e-06	2.92e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—type 2 diabetes mellitus	2.99e-06	2.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.98e-06	2.9e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.97e-06	2.89e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—type 2 diabetes mellitus	2.96e-06	2.88e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.95e-06	2.87e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.95e-06	2.87e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	2.94e-06	2.86e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.94e-06	2.86e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	2.94e-06	2.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—type 2 diabetes mellitus	2.93e-06	2.85e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	2.93e-06	2.85e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	2.93e-06	2.85e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	2.92e-06	2.84e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—type 2 diabetes mellitus	2.91e-06	2.83e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	2.89e-06	2.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	2.89e-06	2.82e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	2.89e-06	2.81e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.89e-06	2.81e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.87e-06	2.79e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.87e-06	2.79e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.87e-06	2.79e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARA—type 2 diabetes mellitus	2.87e-06	2.79e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.85e-06	2.78e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	2.81e-06	2.73e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.8e-06	2.73e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AGT—type 2 diabetes mellitus	2.78e-06	2.7e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.77e-06	2.7e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CALM1—type 2 diabetes mellitus	2.73e-06	2.66e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	2.73e-06	2.66e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—type 2 diabetes mellitus	2.72e-06	2.65e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOA1—type 2 diabetes mellitus	2.69e-06	2.62e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.69e-06	2.62e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	2.68e-06	2.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.67e-06	2.6e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	2.62e-06	2.55e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	2.62e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	2.58e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	2.58e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	2.58e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	2.55e-06	2.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.54e-06	2.47e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	2.53e-06	2.46e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	2.52e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.51e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	2.51e-06	2.44e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.49e-06	2.43e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	2.49e-06	2.43e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	2.48e-06	2.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.46e-06	2.4e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	2.45e-06	2.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	2.45e-06	2.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—type 2 diabetes mellitus	2.44e-06	2.38e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	2.41e-06	2.35e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	2.38e-06	2.31e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—type 2 diabetes mellitus	2.37e-06	2.31e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	2.37e-06	2.3e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	2.36e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.34e-06	2.28e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	2.33e-06	2.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	2.33e-06	2.27e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—INS—type 2 diabetes mellitus	2.33e-06	2.26e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	2.31e-06	2.25e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	2.31e-06	2.25e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	2.29e-06	2.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.28e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—type 2 diabetes mellitus	2.28e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	2.27e-06	2.21e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	2.26e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—type 2 diabetes mellitus	2.25e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—type 2 diabetes mellitus	2.25e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	2.25e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—type 2 diabetes mellitus	2.23e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	2.23e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	2.23e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	2.22e-06	2.16e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	2.22e-06	2.16e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	2.22e-06	2.16e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	2.16e-06	2.1e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	2.13e-06	2.07e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.1e-06	2.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.09e-06	2.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—type 2 diabetes mellitus	2.08e-06	2.02e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—type 2 diabetes mellitus	2.06e-06	2.01e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.05e-06	2e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	2.04e-06	1.99e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—type 2 diabetes mellitus	2.04e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	2.04e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	2.01e-06	1.95e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.96e-06	1.9e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	1.94e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.93e-06	1.87e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.93e-06	1.87e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.92e-06	1.87e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.92e-06	1.86e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	1.91e-06	1.86e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	1.9e-06	1.85e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.89e-06	1.84e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	1.88e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	1.86e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.84e-06	1.79e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.79e-06	1.74e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.76e-06	1.71e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.75e-06	1.71e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—type 2 diabetes mellitus	1.73e-06	1.68e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.72e-06	1.67e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.71e-06	1.66e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.68e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1.68e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.67e-06	1.62e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	1.66e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.64e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	1.63e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.58e-06	1.54e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.58e-06	1.54e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.55e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	1.54e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	1.52e-06	1.48e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.5e-06	1.46e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	1.49e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.47e-06	1.43e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.47e-06	1.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.46e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.45e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.43e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	1.43e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	1.3e-06	1.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1.28e-06	1.24e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	1.26e-06	1.22e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	1.15e-06	1.12e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.1e-06	1.07e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.1e-06	1.07e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	1.01e-06	9.79e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—type 2 diabetes mellitus	9.37e-07	9.12e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	7.74e-07	7.53e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	6.56e-07	6.38e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	5.06e-07	4.92e-06	CbGpPWpGaD
